Latest & greatest articles for Actinic Keratoses

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Actinic Keratoses or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Actinic Keratoses and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Actinic Keratoses

1. Actinic Keratoses

Actinic Keratoses GUIDELINES Evidence-andconsensus-based(S3)Guidelinesforthe TreatmentofActinicKeratosis –InternationalLeagueof DermatologicalSocietiesincooperationwiththeEuropean DermatologyForum –Shortversion R.N.Werner, 1, *E.Stock?eth, 2,22 S.M.Connolly, 3 O.Correia, 4 R.Erdmann, 1 P.Foley, 5,6,7 A.K.Gupta, 8,9 A.Jacobs, 1 H.Kerl, 10 H.W.Lim, 11 G.Martin, 12 M.Paquet, 9 D.M.Pariser, 13 S.Rosumeck, 1 H.-J.R€ owert- Huber, 14 A.Sahota, 15 O.P.Sangueza, 16,17 S.Shumack, 18 B.Sporbeck, 1 (...) ?cation. Br J Dermatol 2007; 156(Suppl. 3): 8– 12. 10 Ackerman AB, Mones JM. Solar(actinic)keratosis is squamous cell carci- noma. Br JDermatol 2006; 155:9–22. 11 Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (‘actinic keratosis’). J Am Acad Dermatol 2000; 42(1 Pt2): 11–17. 12 Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non- melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996

2015 European Dermatology Forum

2. Many interventions effective for actinic keratoses

Many interventions effective for actinic keratoses Many interventions effective for actinic keratoses | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Many interventions effective for actinic keratoses Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

3. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model

Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate (...) -based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Wilson EC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness

2010 NHS Economic Evaluation Database.

4. Guidelines for the management of actinic keratoses

Guidelines for the management of actinic keratoses GUIDELINES DOI 10.1111/j.1365-2133.2006.07692.x Guidelines for the management of actinic keratoses D. de Berker, J.M. McGregor* and B.R. Hughes on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee Bristol Dermatology Centre, Bristol Royal In?rmary, Bristol BS2 8HW, U.K. *Department of Dermatology, St Bartholomew’s and the London NHS Trust, London E1 1BB, U.K. Portsmouth Dermatology Centre, St Mary’s (...) Hospital, Milton Road, Portsmouth PO3 6AD, U.K. Correspondence David de Berker. E-mail: david.deberker@ubht.swest.nhs.uk Accepted for publication 21 May 2006 Key words actinic keratosis, guidelines, treatment Con?icts of interest D. de B., none; J.M.M. has received an honorarium from 3M as an invited member of an advisory board for the treatment of actinic keratoses; B.R.H., none. Members of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee are: A.D. Ormerod (Chairman

2007 British Association of Dermatologists

5. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation

The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation Gupta A K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of topical fluorouracil for the treatment of facial actinic keratoses (AKs). The creams contained 5% fluorouracil (Efudex), 1% fluorouracil (Fluoroplex) and 0.5% fluorouracil (Carac). Treatment regimens approved by the US Food and Drug Administration were considered. Non-approved topical fluorouracil regimens

2002 NHS Economic Evaluation Database.

6. Actinic keratoses

Actinic keratoses Actinic keratoses Actinic keratoses Helfand M, Gorman AK, Mahon S, Chan BK, Swanson N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Helfand M, Gorman AK, Mahon S, Chan BK, Swanson N. Actinic keratoses. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2001 Authors' objectives (...) This report aims to examine evidence about the natural history and management of actinic keratoses (AKs). Authors' conclusions Available data are insufficient to determine whether immediate treatment of all AKs, or a strategy of selective treatment for AKs that develop suspicious characteristics, result in different outcomes. An important information gap is how often squamous cell cancer metastasizes early in its course. The highest priorities for future research are controlled trials of different

2001 Health Technology Assessment (HTA) Database.

7. Actinic keratoses: final report

Actinic keratoses: final report Actinic keratoses: final report Actinic keratoses: final report Helfand M, Gorman A K, Mahon S, Chan B K, Swanson N Authors' objectives To examine evidence about the natural history and management of actinic keratoses (AKs). Searching The authors searched MEDLINE (January 1966 to January 2001), the Cochrane Controlled Trials Register, their own bibliographic databases of articles about skin cancer, and the reference lists of published reviews and other studies (...) in the elderly; and patient-centred research on patients' preferences for, and quality of life related to, different treatments. Funding Agency for Healthcare Research and Quality, contract number 290-97-0018. Bibliographic details Helfand M, Gorman A K, Mahon S, Chan B K, Swanson N. Actinic keratoses: final report. Portland, OR, USA: Oregon Health and Science University, Evidence-Based Practice Center. 2001 Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Keratosis

2001 DARE.